Pleginterferon-α-2a (40kD) -: A review of its use in the management of patients with chronic hepatitis B

被引：8

作者：

Robins, GW ^{[1
]}

Scott, LJ ^{[1
]}

Keating, GM ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland, New Zealand

来源：

DRUGS | 2005年 / 65卷 / 06期

关键词：

D O I：

10.2165/00003495-200565060-00010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Subcutaneous peginterferon-alpha-2a (40kD) [Pegasys((R))] is an effective and reasonably well tolerated treatment for the management of patients with hepatitis B e antigen (HBeAg)-negative or -positive chronic hepatitis B. It was significantly more effective than lamivudine monotherapy at inducing sustained virological response and ALT normalisation in both HBeAg-negative and -positive patients. Notably, the addition of lamivudine to peginterferon-alpha-2a (40kD) conferred no additional benefit versus peginterferon-alpha-2a (40kD) monotherapy. Moreover, in HBeAg-positive patients significantly more peginterferon-alpha-2a (40kD) recipients experienced HBeAg seroconversion than lamivudine recipients. The position of peginterferon-alpha-2a (40kD) relative to other treatment options remains to be fully determined. In the meantime, this agent appears to be a valuable new option for the management of patients with HBeAg-negative or -positive chronic hepatitis B.

引用

页码：809 / 825

页数：17

共 51 条

[41]

*ROCH, PEGASYS ROCH FIL CHR

[42]

*ROCH, PEG PET ALF 2A COMPL

[43]

*ROCH, PEG APPR EUR UN TREA

[44]

*ROCH PHARM SWITZ, 2004, GEN FACH

[45] Diagnosis, management, and treatment of hepatitis C [J].

Strader, DB ;

Wright, T ;

Thomas, DL ;

Seeff, LB .

HEPATOLOGY, 2004, 39 (04) :1147-1171

[46] Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy [J].

Sulkowski, M ;

Wright, T ;

Rossi, S ;

Arora, S ;

Lamb, M ;

Wang, K ;

Gries, JM ;

Yalamanchili, S .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) :214-224

[47]

SY S, 2000, 9 INT C INF DIS 2000

[48]

*US FDA, DRUGS FDA LAB APPR H

[49] Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B [J].

van Zonneveld, M ;

Honkoop, P ;

Hansen, BE ;

Niesters, HGM ;

Murad, SD ;

de Man, RA ;

Schalm, SW ;

Janssen, HLA .

HEPATOLOGY, 2004, 39 (03) :804-810

[50] SF-36 health survey update [J].

Ware, JE .

SPINE, 2000, 25 (24) :3130-3139

← 1 2 3 4 5 6 →